Cerdulatinib in Relapsed/Refractory B-Cell Malignancies

Ian W. Flinn, MD, PhD

Ian W. Flinn, MD, PhD, director, Blood Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses a phase I story which examined cerdulatinib in patients with relapsed/refractory B-cell malignancies.